Safety Issue Puts Daclizumab in Doubt for MS MedPage Today LYON, France -- Daclizumab, a biologic drug targeting the interleukin-2 pathway, showed sustained efficacy in the second year of a phase II trial in multiple sclerosis, but serious autoimmune issues also emerged, researchers said here. In a randomized ... |
